Replication-Deficient Sindbis Virus Controls for Nucleic Acid Assays

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing nucleic acid-based diagnostic devices lack effective quality controls that can simulate the entire analytical process, including sample lysis and nucleic acid extraction, and are often unstable or pose safety risks, limiting their reliability and availability.

Innovation Solution

Replication-deficient recombinant Sindbis viruses are engineered to include an open reading frame for Sindbis non-structural proteins and a heterologous RNA sequence, which can be used as controls in nucleic acid diagnostic assays, simulating the entire analytical process and providing stability and safety.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If natural material derived from infected patients is used as quality control, then the control behaves very similarly to a clinical sample, but the availability, concentration and stability are limited and unpredictable

Engineering Contradiction:
Improvesimilarity to clinical sampleVSAvoidstability
Core Design Contradiction:
ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent creates a synthetic copy of viral RNA that mimics the target pathogen's RNA sequence and structure. This synthetic RNA control replicate allows the diagnostic assay to function exactly as it would with real patient samples, providing reliable performance monitoring without the instability and availability issues of natural patient-derived materials

Inventive Principle:
Principle #26Copying

Solution Approach 2:

The patent modifies the RNA sequence by incorporating synthetic elements and adjusting compositional parameters such as nucleotide composition and secondary structure. These parameter changes enable the control to maintain stable physical and chemical properties while still behaving like clinical samples in the diagnostic assay context

Inventive Principle:
Principle #35Parameter changes

2Stability of the object's composition

If cultured virus is used to generate positive controls, then availability improves, but virus culture is often unavailable or technologically difficult and safety risks increase

Engineering Contradiction:
ImproveavailabilityVSAvoidsafety risks
Core Design Contradiction:
Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent employs a disposable, non-infectious synthetic RNA control that eliminates the need for maintaining live virus cultures. This single-use control material provides consistent availability without the safety hazards of handling pathogenic viruses, as it cannot replicate or cause infection

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent introduces a synthetic RNA intermediary that mediates the function of viral positive controls without requiring actual virus particles. This intermediary provides the necessary RNA target for assay validation while eliminating the biological hazards associated with cultured viruses

Inventive Principle:
Principle #24Intermediary (Mediator)

3Object-affected harmful factors

If non-infectious DNA plasmid or purified RNA transcripts are used as controls, then safety improves, but stability at ambient temperatures remains limited

Engineering Contradiction:
ImprovesafetyVSAvoidstability at ambient temperature
Core Design Contradiction:
Object-affected harmful factorsVSStability of the object's composition

Solution Approach 1:

The patent creates a composite control material that combines synthetic RNA with stabilizing formulations and protective carriers. This composite structure maintains the safety advantages of non-infectious materials while dramatically improving ambient temperature stability through the synergistic combination of multiple stabilizing components

Inventive Principle:
Principle #40Composite materials

Data Source

PatentEP3310368B1Sindbis control virus
Publication Date: 2025.07.16 LGC CLINICAL DIAGNOSTICS INC
  • EP3310368B1 patent drawingFigure 1
  • EP3310368B1 patent drawingFigure 2
  • EP3310368B1 patent drawingFigure 3

AI summary

Disclosed are compositions and methods related to replication deficient Sindbis viruses that are able to function as controls for nucleic acid diagnostic assays (e.g., nucleic acid sequencing based assays and/or nucleic acid amplification based assays).